Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
|
IN |
|
H
|
Hunan Junxin Environmental Protection Co Ltd
SZSE:301109
|
CN |
Balance Sheet
Balance Sheet Decomposition
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd
Balance Sheet
Lincoln Pharmaceuticals Ltd
| Mar-2005 | Mar-2006 | Mar-2007 | Mar-2008 | Mar-2009 | Mar-2010 | Mar-2011 | Mar-2012 | Mar-2013 | Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||
| Cash & Cash Equivalents |
2
|
11
|
15
|
25
|
35
|
26
|
115
|
120
|
151
|
105
|
115
|
125
|
117
|
146
|
55
|
122
|
114
|
183
|
225
|
138
|
224
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
94
|
50
|
40
|
33
|
31
|
66
|
55
|
122
|
114
|
183
|
225
|
57
|
134
|
|
| Cash Equivalents |
2
|
11
|
15
|
25
|
35
|
26
|
115
|
120
|
58
|
55
|
75
|
92
|
86
|
80
|
0
|
0
|
0
|
0
|
0
|
81
|
90
|
|
| Short-Term Investments |
11
|
5
|
5
|
8
|
10
|
109
|
10
|
41
|
0
|
0
|
0
|
11
|
103
|
110
|
181
|
342
|
808
|
970
|
914
|
1 389
|
1 744
|
|
| Total Receivables |
225
|
316
|
264
|
293
|
360
|
433
|
807
|
833
|
887
|
1 148
|
1 441
|
798
|
917
|
1 095
|
1 456
|
1 335
|
1 464
|
1 513
|
1 708
|
2 160
|
2 236
|
|
| Accounts Receivables |
17
|
19
|
20
|
20
|
30
|
25
|
70
|
107
|
748
|
890
|
1 190
|
798
|
907
|
1 094
|
1 225
|
1 013
|
1 113
|
1 159
|
1 365
|
1 618
|
1 666
|
|
| Other Receivables |
209
|
297
|
244
|
273
|
330
|
408
|
737
|
726
|
139
|
257
|
251
|
0
|
10
|
0
|
232
|
322
|
351
|
354
|
344
|
541
|
571
|
|
| Inventory |
80
|
107
|
125
|
123
|
143
|
230
|
261
|
214
|
193
|
238
|
218
|
275
|
373
|
454
|
362
|
474
|
466
|
727
|
700
|
772
|
787
|
|
| Other Current Assets |
0
|
0
|
56
|
7
|
13
|
91
|
6
|
8
|
0
|
0
|
0
|
268
|
301
|
379
|
187
|
206
|
212
|
135
|
125
|
11
|
12
|
|
| Total Current Assets |
319
|
438
|
466
|
455
|
562
|
888
|
1 199
|
1 216
|
1 232
|
1 491
|
1 774
|
1 477
|
1 811
|
2 183
|
2 240
|
2 480
|
3 065
|
3 529
|
3 672
|
4 467
|
4 999
|
|
| PP&E Net |
83
|
82
|
86
|
112
|
169
|
221
|
316
|
467
|
624
|
628
|
629
|
913
|
997
|
1 073
|
1 134
|
1 132
|
1 119
|
1 476
|
1 569
|
1 825
|
1 860
|
|
| PP&E Gross |
83
|
82
|
86
|
112
|
169
|
221
|
0
|
467
|
0
|
0
|
0
|
0
|
0
|
0
|
1 134
|
1 132
|
1 119
|
1 476
|
1 569
|
1 825
|
1 860
|
|
| Accumulated Depreciation |
31
|
36
|
41
|
48
|
56
|
67
|
0
|
107
|
0
|
0
|
0
|
0
|
0
|
0
|
169
|
235
|
308
|
384
|
460
|
563
|
688
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
4
|
49
|
47
|
53
|
3
|
4
|
3
|
4
|
4
|
4
|
4
|
3
|
3
|
4
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
42
|
0
|
0
|
0
|
92
|
92
|
92
|
92
|
92
|
92
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
133
|
364
|
460
|
428
|
125
|
252
|
88
|
91
|
160
|
152
|
258
|
277
|
601
|
661
|
1 068
|
|
| Long-Term Investments |
0
|
0
|
0
|
43
|
0
|
0
|
0
|
4
|
4
|
4
|
0
|
1
|
1
|
1
|
2
|
2
|
7
|
19
|
5
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
27
|
0
|
0
|
0
|
20
|
61
|
29
|
28
|
32
|
49
|
40
|
24
|
47
|
38
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
42
|
0
|
0
|
0
|
92
|
92
|
92
|
92
|
92
|
92
|
0
|
0
|
0
|
0
|
|
| Total Assets |
402
N/A
|
521
+29%
|
552
+6%
|
611
+11%
|
730
+20%
|
1 109
+52%
|
1 653
+49%
|
2 123
+28%
|
2 369
+12%
|
2 598
+10%
|
2 580
-1%
|
2 757
+7%
|
3 053
+11%
|
3 472
+14%
|
3 660
+5%
|
3 894
+6%
|
4 594
+18%
|
5 344
+16%
|
5 874
+10%
|
7 003
+19%
|
7 970
+14%
|
|
| Liabilities | ||||||||||||||||||||||
| Accounts Payable |
75
|
80
|
74
|
81
|
108
|
177
|
226
|
421
|
475
|
665
|
453
|
398
|
325
|
435
|
440
|
512
|
568
|
717
|
512
|
724
|
849
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
42
|
16
|
47
|
59
|
61
|
69
|
79
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
404
|
466
|
549
|
485
|
507
|
524
|
450
|
486
|
301
|
38
|
0
|
20
|
20
|
11
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
16
|
46
|
0
|
0
|
0
|
0
|
63
|
58
|
18
|
4
|
4
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
17
|
28
|
43
|
61
|
80
|
100
|
127
|
116
|
159
|
161
|
147
|
126
|
71
|
71
|
52
|
85
|
117
|
109
|
130
|
118
|
133
|
|
| Total Current Liabilities |
92
|
108
|
116
|
143
|
188
|
277
|
772
|
1 049
|
1 183
|
1 311
|
1 107
|
1 048
|
909
|
1 049
|
853
|
656
|
736
|
905
|
723
|
923
|
1 062
|
|
| Long-Term Debt |
97
|
132
|
135
|
131
|
156
|
271
|
41
|
143
|
171
|
192
|
255
|
194
|
124
|
69
|
17
|
9
|
1
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
18
|
15
|
15
|
16
|
22
|
29
|
43
|
52
|
48
|
40
|
46
|
45
|
59
|
72
|
56
|
54
|
57
|
65
|
79
|
115
|
130
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
43
|
42
|
37
|
29
|
3
|
3
|
3
|
4
|
4
|
4
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
28
|
29
|
33
|
30
|
30
|
32
|
35
|
36
|
37
|
41
|
43
|
45
|
47
|
37
|
61
|
|
| Total Liabilities |
207
N/A
|
254
+23%
|
266
+5%
|
289
+9%
|
366
+27%
|
576
+58%
|
885
+53%
|
1 315
+49%
|
1 476
+12%
|
1 609
+9%
|
1 467
-9%
|
1 322
-10%
|
1 130
-15%
|
1 230
+9%
|
966
-21%
|
763
-21%
|
841
+10%
|
1 015
+21%
|
849
-16%
|
1 075
+26%
|
1 253
+17%
|
|
| Equity | ||||||||||||||||||||||
| Common Stock |
60
|
76
|
76
|
76
|
86
|
113
|
163
|
163
|
163
|
163
|
163
|
163
|
200
|
200
|
200
|
200
|
200
|
200
|
200
|
200
|
200
|
|
| Retained Earnings |
41
|
57
|
76
|
112
|
145
|
193
|
225
|
264
|
730
|
825
|
950
|
1 273
|
1 724
|
2 042
|
1 846
|
2 288
|
2 910
|
3 484
|
4 183
|
5 086
|
5 873
|
|
| Additional Paid In Capital |
93
|
133
|
133
|
133
|
133
|
226
|
381
|
381
|
0
|
0
|
0
|
0
|
0
|
0
|
646
|
646
|
646
|
646
|
646
|
646
|
646
|
|
| Other Equity |
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
3
|
2
|
5
|
4
|
3
|
|
| Total Equity |
195
N/A
|
266
+36%
|
286
+7%
|
322
+13%
|
364
+13%
|
533
+46%
|
768
+44%
|
808
+5%
|
893
+11%
|
988
+11%
|
1 113
+13%
|
1 436
+29%
|
1 924
+34%
|
2 242
+17%
|
2 693
+20%
|
3 131
+16%
|
3 753
+20%
|
4 329
+15%
|
5 025
+16%
|
5 928
+18%
|
6 717
+13%
|
|
| Total Liabilities & Equity |
402
N/A
|
521
+29%
|
552
+6%
|
611
+11%
|
730
+20%
|
1 109
+52%
|
1 653
+49%
|
2 123
+28%
|
2 369
+12%
|
2 598
+10%
|
2 580
-1%
|
2 757
+7%
|
3 053
+11%
|
3 472
+14%
|
3 660
+5%
|
3 894
+6%
|
4 594
+18%
|
5 344
+16%
|
5 874
+10%
|
7 003
+19%
|
7 970
+14%
|
|
| Shares Outstanding | ||||||||||||||||||||||
| Common Shares Outstanding |
6
|
8
|
8
|
8
|
8
|
11
|
16
|
16
|
16
|
16
|
16
|
16
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
|